Ann Fieuw

564 total citations
13 papers, 349 citations indexed

About

Ann Fieuw is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ann Fieuw has authored 13 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ann Fieuw's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Sphingolipid Metabolism and Signaling (3 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Ann Fieuw is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Sphingolipid Metabolism and Signaling (3 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Ann Fieuw collaborates with scholars based in Belgium, United Kingdom and Netherlands. Ann Fieuw's co-authors include Paul Ford, Wim Wuyts, Toby M. Maher, Sonia Dupont, Julie Desrivot, Ellen M. van der Aar, Simone Stutvoet, Nadia Verbruggen, Walid Abi‐Saab and Kevin K. Brown and has published in prestigious journals such as Journal of the American Society of Nephrology, Clinical Pharmacokinetics and Journal of Hypertension.

In The Last Decade

Ann Fieuw

13 papers receiving 343 citations

Peers

Countries citing papers authored by Ann Fieuw

Since Specialization

Citations

This map shows the geographic impact of Ann Fieuw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Fieuw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Fieuw more than expected).

Fields of papers citing papers by Ann Fieuw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Fieuw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Fieuw. The network helps show where Ann Fieuw may publish in the future.

Co-authorship network of co-authors of Ann Fieuw

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Fieuw. A scholar is included among the top collaborators of Ann Fieuw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Fieuw. Ann Fieuw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	The MANGROVE Phase 2 Trial: Study Design and Baseline Characteristics of Patients With Autosomal Dominant Polycystic Kidney Disease 2022 ·Journal of the American Society of Nephrology ·Ron T. Gansevoort, Antonio Pisani, Miguel Hueso, (unknown), (unknown), (unknown), Ann Fieuw, Władysław Sułowicz	1
2	Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip 2021 ·Clinical Pharmacology in Drug Development ·Ellen van der Aar, H. Deckx, Sonia Dupont, Ann Fieuw, (unknown), S. Larsson, André Struglics, Stefan Lohmander, Alain Lalande, (unknown), David Amantini, Paul Passier	17
3	Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis 2020 ·Contemporary Clinical Trials ·Lisa Lancaster, Ann Fieuw, (unknown), Paul Ford, Steven D. Nathan	9
4	The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis 2020 ·The Journal of Heart and Lung Transplantation ·Kenneth Sinclair, Stephanie T. Yerkovich, Peter Hopkins, Ann Fieuw, Paul Ford, Joseph E. Powell, Brendan O’Sullivan, Daniel C. Chambers	8
5	Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis 2019 ·Clinical Pharmacokinetics ·Amit Taneja, Julie Desrivot, Paul M. Diderichsen, Roland Blanqué, (unknown), (unknown), Ann Fieuw, Ellen van der Aar, Florence Namour	10
6	Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials 2019 ·The Journal of Clinical Pharmacology ·Ellen van der Aar, Julie Desrivot, Sonia Dupont, Bertrand Heckmann, Ann Fieuw, Simone Stutvoet, (unknown), (unknown), Eric Helmer	34
7	Rationale, Design and Objectives of Two Phase III, Randomised, Placebo-Controlled Studies of GLPG1690, a Novel Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (ISABELA 1 and 2) 2019 ·Toby M. Maher, (unknown), David J. Lederer, (unknown), (unknown), Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, (unknown), (unknown)	3
8	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) 2019 ·BMJ Open Respiratory Research ·Toby M. Maher, Michael Kreuter, David J. Lederer, Kevin K. Brown, Wim Wuyts, Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, Walid Abi‐Saab, Marlies Wijsenbeek	78
9	Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial 2018 ·The Lancet Respiratory Medicine ·Toby M. Maher, Ellen M. van der Aar, (unknown), (unknown), Julie Desrivot, Sonia Dupont, (unknown), Paul Ford, Ann Fieuw, Wim Wuyts	175
10	Late Breaking Abstract - Idiopathic Pulmonary Fibrosis – a worldwide review of ‘real’ life’ practice: experience from a treatment feasibility review in 41 countries 2018 ·Marlies Wijsenbeek, (unknown), Joëlle Thonnard, Ann Fieuw, Paul Ford, Eva Santermans, (unknown), Toby M. Maher	1
11	Belgian global implementation of cardiovascular and stroke risk assessment study: methods and baseline data of the BELGICA-STROKE STUDY 2011 ·European Journal of Cardiovascular Prevention & Rehabilitation ·Patricia Van der Niepen, Vincent Thijs, Dirk Devroey, Ann Fieuw, M. Dramaix, Philippe van de Borne	2
12	HYPERTENSIVE PATIENTS WITH ATRIAL FIBRILLATION HAVE A HIGH PREVALENCE OF RENAL DISEASE: RESULTS OF THE BELGICA-STROKE STUDY: PP.16.95 2010 ·Journal of Hypertension ·Patricia Van der Niepen, Vincent Thijs, P van de Borne, M. Dramaix, Ann Fieuw, Dirk Devroey	1
13	A Web- and Case-based Learning Program for Postgraduate Students in Occupational Medicine 2008 ·International Journal of Occupational and Environmental Health ·Lutgart Braeckman, Ann Fieuw, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact